RxDoctor Payments Data

Augustine Njoku, MD

Cardiovascular Disease · Tyler, TXNPI 1174784904

Payments from drug & device makers

$18,904in general payments, 2019–2025

Across 271 payments — averaging $69.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Novo Nordisk AS$7K
  • Abbott$643
  • Novartis$642
  • Shockwave Medical, Inc$438
  • Inari Medical, Inc.$430
  • plus $2K from 25 others

What the payments were for

  • Travel & lodging$6,69256%
  • Food & beverage$5,19844%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,904 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$316,615
Medicare patients
1,928
Services billed
5,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban361$309,435
JardianceEmpagliflozin87$58,776
BrilintaTicagrelor97$52,665
EntrestoSacubitril/Valsartan52$52,321
XareltoRivaroxaban57$49,673
Repatha SureclickEvolocumab43$25,823
FarxigaDapagliflozin Propanediol20$13,386
Atorvastatin Calcium544$3,929
Ranolazine ErRanolazine41$3,710
Isosorbide Dinitrate92$3,263
ClopidogrelClopidogrel Bisulfate451$3,262
Metoprolol Succinate366$3,218
Carvedilol371$2,245
Lisinopril389$2,000
Potassium Chloride74$1,675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$211$309,435361 claims
AstraZenecaBrilinta, Farxiga$68$66,051117 claims
Boehringer IngelheimJardiance$66$58,77687 claims
NovartisEntresto$642$52,32152 claims
Johnson & JohnsonXarelto$251$49,67357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →